Abbott Laboratories (ABT)
NYSE
Key stats Fiscal year 2025
Income statement
- Revenue
- 44,328,000,000 5.7%
- Net income
- 6,524,000,000 -51.3%
- Operating income
- 8,053,000,000
- Earnings per share
- 3.73 -51.4%
- R&D expense
- 2,942,000,000
Growth and profitability
- Operating margin
- 18.17
- Net margin
- 14.72
- Return on equity
- 12.51
- Return on assets
- 7.52
- Free cash flow margin
- 16.68
Balance sheet
- Total assets
- 86,713,000,000
- Shareholders' equity
- 52,130,000,000
- Cash and equivalents
- 8,522,000,000
- Debt
- 12,929,000,000
- Net debt
- 4,407,000,000
- Current ratio
- 1.58
- Debt to equity
- 0.25
Cash flow and ratios
- Operating cash flow
- 9,566,000,000
- Free cash flow
- 7,395,000,000
Shareholder returns
- Dividend per share
- 2.40
- Dividends paid
- 4,116,000,000
- Share buybacks
- 893,000,000
- Shares outstanding
- 1,731,941,601
- Book value per share
- 30.10
Company information
- Headquarters
- Abbott Park, IL
- Exchange
- NYSE
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Abbott Laboratories trades on NYSE under the ticker symbol ABT. This page brings together its price chart, company profile, key financial figures and technical indicators.